TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean AMH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: AMH per follicle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Dose of ovulation induction medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AK recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Negative observations
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of catheter patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients completing TPN therapy successfully
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of catheter occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastroduodenal damage severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Biopsy score (BS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cure rate of stress incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative 1-hour pad test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal erosion/infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of CaP on biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Ki-67
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: children's self‐reports of hostile attributional biases
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: children's self‐reports of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Apoptosis in polymorphonuclear cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Granulomas along the line of staples
Endpoint domain: Adverse events/effects
Primary endpoint: Pain on defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Potential deaths avoided/year
Endpoint domain: Mortality/survival
Primary endpoint: Median GE time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Excessive gestational weight gain (GWG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight retention at 2 months postpartum (mopp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean self‐monitored blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: morning blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Days to sustainable return-to-work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of post-concussion symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Contrast-Induced Acute Kidney Injury (CI-AKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to achieve baseline blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of subjects achieving baseline blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Intraoperative accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Trust in navigation system
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Surgical procedure reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: motor and phonic tics scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global impairment scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: global severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pre-meal glucose levels before lunch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC measuring over 140 mg/dl 3 h after breakfast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC measuring over 140 mg/dl 3 h after lunch
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite morbidity and mortality endpoint
Endpoint domain: Mortality/survival
Primary endpoint: SF-36 Mental Component Summary score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: days lost to death
Endpoint domain: Mortality/survival
Primary endpoint: patient journey score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: cannula insertion success rate on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ADAS-Cog score worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean haemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean alanine aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean aspartate aminotransferase (AST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seeking testing or treatment for sexually transmitted infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence, spectrum, and severity of reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Achieving SBP/DBP < 140/90 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NHS costs of treating women with hysteroscopic surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Costs incurred by women undergoing hysteroscopic surgery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: >50% reduction in initial pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life measured using visual analog scales
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Size of uterine wall defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined fatal coronary heart disease (CHD) or non-fatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: mUFC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Late-night salivary cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diabetes classification (HbA1c and FPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: DTP3 completion within two months from the time of registration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DTP3 completion within 180 days of birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DTP3 completion within two camps after DTP1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean severity of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: overall recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence and severity of emergence agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life (QoL) at week 12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: suppression of menstruation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cocaine-free days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean time to administration of IM epinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Errors in management
Endpoint domain: Adverse events/effects
Primary endpoint: Wound area decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound depth decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local perfusion increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of polyps detected per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rumination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Routine stocking of naloxone
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Availability of naloxone on the day of contact
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average out-of-pocket price of naloxone nasal spray
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incidence of postoperative hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical NEDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuroradiological NEDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall NEDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioural intention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Post-operative concentrations of myocardial-specific proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-operative concentrations of pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TAC level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hospitalization for migraine
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Oxygenation levels (PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxygenation levels (SaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: modified Lund-Kennedy endoscopic scores reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postbronchodilator FEV₁
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Likelihood of progression to fibrocavernous tuberculosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of 12-month course of therapy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Need for surgical treatment of pulmonary tuberculosis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Energy efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCyR rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effectiveness of routine follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost-effectiveness of routine follow up
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Zinc concentration in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose concentration in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: degree of pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Quality of life (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Quality of life (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of in-office ICD follow-ups
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Leukopenia frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Median dose intensity delivered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heparin dosage requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intensity of tinnitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in IID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positional reproducibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal tissue sparing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scanning/treatment setup times
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to first symptomatic arrhythmia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the 3-hour blood glucose response curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Back Depression Inventory (BDI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: State‐trait anxiety inventory (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: gastrointestinal complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mobility of devices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of literature search
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with screen size
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak Inspiratory Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increase in tooth lengths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total doses of alfentanil administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PPD (Pocket Depth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood urea levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean daily step count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean absolute difference between observed and predicted values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of PEX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual incidence of OAG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of glaucoma associated with PEX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of post-concussion symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Normalization of resting blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in maximum oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to diabetes diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Drop in platelets >25%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Systemic Oxygen Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean area under the plasma concentration vs time curve (AUC) for omeprazole sulphone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC ratio of omeprazole sulphone to omeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak concentration (Cmax) of omeprazole sulphone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score on the Brief Psychiatric Rating Scale (BPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eGFR at one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: increase in eGFR from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement in HAMD work/activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvement in Maier scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in SASS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: probing bone-level gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CC-IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: BA-FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Emotional functioning at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total health service utilisation post-intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Supportive care utilisation post-intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Spectacle independence for near vision
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in sexual distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increased perception of genital arousal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Flushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for detecting prior MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specificity for detecting prior MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall accuracy for diagnosing previous MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: F(1+2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of subjects exhibiting a seroprotective immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall compliance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of control of AHT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of hot flushes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of fibrinolysis during cardiopulmonary bypass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dietary self-monitoring adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative dose for LTD(4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Potency ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 or worse toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: use of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for resuturing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: ACR20 response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevations in alanine aminotransferase
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to increase physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postextubation pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Mean percent change of normalized T2 SI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of grade ≥2 dysphagia
Endpoint domain: Adverse events/effects
Primary endpoint: Power mobility proficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall grade 2 or higher acute toxic effects
Endpoint domain: Adverse events/effects
Primary endpoint: Trouble meeting family needs
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Cotinine-confirmed smoking cessation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma LDL cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional capacities (METS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total pain experienced
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spent less of the study period in moderate or severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintaining intraocular pressure less than 18 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes